Advertisement
The Body: The Complete HIV/AIDS Resource Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
TheBody.com/TheBodyPRO.com cover the XVIII International AIDS Conference (AIDS 2010)
  

Use of Antiretrovirals for Prevention: PrEP, PEP and ART

July 21, 2010

Transcript (.pdf)

For more information on this session, including access to speaker presentations, please see the conference Programme-at-a-Glance.

Despite years of prevention efforts, HIV incidence has been inadequately controlled and the HIV/AIDS epidemic remains a global public health crisis. The global response has not been sufficient and the current economic crisis threatens recent gains. Given the gravity of the situation, it is not surprising that the question of how best to use antiretroviral treatment (ART) for prevention has emerged. There is increasing evidence that ART has an effect on both horizontal and vertical HIV transmission, and that it reduces mortality in TB/HIV co-infection. Some experts believe that the implementation of voluntary universal testing programmes, with immediate initiation of ART for individuals who test positive, could significantly reduce HIV incidence. However, expert evaluation and further research are required to assess this novel approach, evaluate its appropriateness and feasibility, and define the requirements for public health decision-making on how to best use ART for prevention. The benefits of antiretroviral drugs can also be extended further into prevention for HIV-negative individuals through antiretroviral pre- and post-exposure prophylaxis. A number of clinical trials to study the effectiveness of pre- exposure prophylaxis are ongoing and results will most likely be available before data from planned field trials on the use of universal test and treat (for HIV-positive individuals). This session will explore the potential synergies of the use of antiretrovirals for HIV-positive and HIV-negative individuals.

Presentations in This Session:

Introduction

Helen Rees (South Africa)
Teguest Guerma (Kenya)

Potential Role of PrEP/PEP for HIV Prevention in Men Who Have Sex with Men
Godefridus J. P. van Griensven (Netherlands)

Impact of Antiretroviral Therapy on HIV Transmission: Results from a Five Year HAART Coverage Expansion in British Columbia, Canada
Julio Montaner (Canada)

Modelling Potential Synergies of PrEP and ART for Prevention
Geoffrey Garnett (United Kingdom)

ART for Prevention: Opportunities and Challenges
Myron Cohen (United States)

Conclusions

Use of Antiretroviral for Prevention: PrEP, PEP and ART (.mp3)


This information was reprinted from kff.org with permission from the Henry J. Kaiser Family Foundation. You can view all of Kaiser's coverage of the XVIII International AIDS Conference at http://www.kff.org/aids2010. © Henry J. Kaiser Family Foundation. All rights reserved.



  

This article was provided by Henry J. Kaiser Family Foundation. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
 
See Also
More News and Research on HIV Medications for HIV Prevention

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:



Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

AIDS 2010
Home
Choose a Topic:
Previous Conferences

Advertisement